Published in Drug Law Weekly, November 21st, 2006
Nabi-HB (hepatitis B immune globulin (human)) revenues were lower as the company continues to negotiate the terms of a supply contract with one of its product distributors. Cash, cash equivalents and marketable securities were $64.9 million at the end of the third quarter of 2006. During the third quarter of 2006, cash used in operating activities was $4.3 million compared...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.